Home > Insider Trading > Filing (0001586939-14-000004)

Filing Details

Accession Number:: 0001586939-14-000004
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-05-05 18:48:55
Reporting Period:: 2014-05-01

Filing Date:: 2014-05-05
Accepted Time:: 2014-05-05 17:48:55
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1434316	Fate Therapeutics Inc	FATE	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1586939	D Peter Flynn	C/O Fate Therapeutics, Inc. 3535 General Atomics Court, Suite 200 San Diego CA 92121	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-05-01	6,925	$1.63	13,656	No	4	M	Direct
Common Stock	Acquisiton	2014-05-01	1,100	$1.63	14,756	No	4	M	Direct
Common Stock	Acquisiton	2014-05-01	422	$1.37	15,178	No	4	M	Direct
Common Stock	Disposition	2014-05-01	9,793	$7.07	5,385	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2014-05-01	6,925	$0.00	6,925	$1.63
Common Stock	Stock Option (right to buy)	Disposition	2014-05-01	1,100	$0.00	1,100	$1.63
Common Stock	Stock Option (right to buy)	Disposition	2014-05-01	422	$0.00	422	$1.37

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
30,816	2022-02-08	No	4	M	Direct
25,300	2022-02-08	No	4	M	Direct
19,872	2022-07-23	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2013.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.19, inclusive.
The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
The shares subject to this option shall vest and become exercisable at the rate of 1/4th of the shares on May 30, 2012 and 1/48th of the shares each month thereafter such that this option is fully exercisable on May 30, 2015. This option is subject to accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer.
Not applicable.
The shares subject to this option shall vest and become exercisable in 24 equal monthly installments beginning on the date one month after the completion of the Issuer's initial public offering. This option is subject to accelerated vesting upon a change of control of the Issuer after the completion of the Issuer's initial public offering.
The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on August 3, 2012 such that this option is fully exercisable on July 3, 2016. This option is subject to accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer.